VIDEO: Interesting data on KRAS inhibitors; New mutant-specific inhibitors "quite exciting"
Click Here to Manage Email Alerts
In this video, Lillian L. Siu, MD, FRCPC, senior medical oncologist at Princess Margaret Cancer Centre in Toronto, ON, Canada, discussed presentations on new drugs on the horizon, including mutant-specific inhibitors and FGFR2-inhibitors.
"These are going to be very interesting drugs to keep an eye out for in terms of their role in cancer," Siu said.
In addition, Siu touched on presentations on KRAS inhibitors and inhibitors beyond KRAS G12C, as well as drugs designed to interrogate KRAS G12D, which is just beginning to enter the clinic, she said.
"This has created a lot of attention —especially in social media — on cancers such as [those involving the] pancreas, which has a high percentage of KRAS G12D mutations,” she added, saying it’s of particular interest because it has been “a previously considered undruggable target."
Collapse
Christensen JG. Discovery and characterization of MRTX1133, a selective non-covalent inhibitor of KRASG12D; Presented at: 2021 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (virtual meeting); Oct. 7-10, 2021.
Goyal L. First results of RLY-4008, a potent and highly selective FGFR2 inhibitor in a first-in-human study in patients with FGFR2-altered cholangiocarcinoma and multiple solid tumors; Presented at: 2021 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (virtual meeting); Oct. 7-10, 2021.
Kelsey S. Discovery and development of RAS(ON) inhibitors beyond KRAS G12C; Presented at: 2021 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (virtual meeting); Oct. 7-10, 2021.
Read more about
Click Here to Manage Email Alerts